Skip to content
MarketScale
‹ Back to IndustriesSciences

The Space Race Is Back and Heading to the Public Market

The return of the space race has more companies and investors looking for ways to get into the industry. Astra is the first rocket company since 1990 to announce it will go public, and the latest space SPAC since Virgin Galactic in 2019. The California garage startup, which now occupies a quarter-of-a-million square foot facility…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Sciences · AstraBloombergOuter SpacePublic
Share
The Space Race Is Back and Heading to the Public Market

Key takeaways

01

The return of the space race has more companies and investors looking for ways to get into the industry.

02

Astra is the first rocket company since 1990 to announce it will go public, and the latest space SPAC since Virgin Galactic in 2019.

03

The California garage startup, which now occupies a quarter-of-a-million square foot facility…

The return of the space race has more companies and investors looking for ways to get into the industry. Astra is the first rocket company since 1990 to announce it will go public, and the latest space SPAC since Virgin Galactic in 2019. The California garage startup, which now occupies a quarter-of-a-million square foot facility in Alameda, is valued at $2 Billion. The company provides rocket launches for $3 Million each, significantly less than that of SpaceX and Rocket Lab. Watch Emily Chang’s report above or read the transcript below.

From home garage to full fledged rocket company, Astra is the latest upstart looking to make its name in the space race with big ambitions to ramp up to a rocket launch a day delivering things like satellites, supplies and other cutting edge technology to space within the next four years. To raise capital and fast CEO Chris Kemp plans to capitalize on the SPAC craze, and take the company public this year in a merger with Holicity, run by Billionaire and former telecom mogul Craig McCaw.

Astra would be the latest space back since virgin galactic, which merged with social capital in 2019. Astra, though, wasn’t founded by a billionaire. It started operations in a San Francisco garage with limited funding. The company now designs tests and manufactures a line of small, relatively cheap rockets at its current factory just over the Bay Bridge in Alameda, California. A former Naval base, now home to served as a jet engine research facility and gained popularity as the site of Discovery Channel’s Mythbusters.

The team occupies a quarter of a million square foot research facility where researchers, engineers and scientists can all work under one roof, eliminating the need for complex logistics. In December, successfully launched their 3.2 rocket from the Pacific spaceport complex in Kodiak, Alaska, but nearly missed its orbit target. Kemp has said some minor tweaks should resolve the issue and allow them to fly again this summer.

Spacex is currently the dominant maker of large rockets designed to carry thousands of pounds of payload to orbit. But it comes with cost, charging roughly $60 million per launch. By comparison, rocket lab, founded in New Zealand, and now headquartered in the u.s., starts at around $6 million a launch. Astra is now only capable of smaller payloads than both companies, but will charge just $3 million per launch over the next few years.

The first and last rocket company to go public with Orbital Sciences Corporation back in 1990. It since merged into a subsector of Northrop Grumman. Astra will be the only publicly traded company focused solely on building and launching rockets when it begins trading later this year if Kemp can execute his big vision.

As more and more players join the space race, opportunities will become abundant for investors to enter the arena. But questions still remain around when the industry starts making money. Morgan Stanley believes the global space industry could generate more than a trillion in revenue or more in 2040, up from $350 billion right now, over half the growth coming from satellite broadband technology. And as rocket launches get cheaper and more companies look to commercialize space, profitability may soon be taking off.

*Bloomberg contributed to this article

Follow us on social media for the latest updates in B2B!

Twitter – @MarketScale

Facebook – facebook.com/marketscale

LinkedIn – linkedin.com/company/marketscale

About the author

S
Sciences

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Sciences expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's Sciences expertise into the articles, video, and social content B2B marketing buyers in your industry are searching for. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Sciences Insights

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

The pharmaceutical industry is facing a significant challenge as over $300 billion in branded pharmaceutical revenue is set to lose patent protection by 2030. This revenue gap is driving the largest merger and acquisition cycle seen in a decade, with companies seeking external growth through acquisitions. This shift is impacting the entire life sciences supply chain, prompting strategic changes across the industry.

  • 01Over $300 billion in pharmaceutical revenue is at risk due to patent expirations by 2030.
  • 02Big Pharma is engaging in an aggressive cycle of mergers and acquisitions.
  • 03The acquisitions are reshaping the life sciences supply chain.

Jun 29, 2026

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences has initiated a Phase I clinical study at its UK facility for an oral solid dose formulation designed using artificial intelligence — what the company believes is the first AI-formulated drug to reach human clinical evaluation. The study, cleared by the UK's Medicines and Healthcare products Regulatory Agency, will assess safety and pharmacokinetics in healthy volunteers. The program, which used Intrepid Labs' machine learning algorithm, signals a broader shift in how contract drug development organizations are integrating AI across formulation and clinical workflows.

  • 01Quotient Sciences initiated a Phase I study of an AI-designed oral solid dose formulation at its UK facility following MHRA approval — the first such case the company believes has been reported.
  • 02The formulation was developed using Intrepid Labs' advanced machine learning algorithm in combination with Quotient Sciences' Translational Pharmaceutics platform.
  • 03The milestone is part of a broader CRDMO strategy to embed AI-enabled approaches across formulation development and clinical workflows, with implications for the wider contract pharma sector.

Jun 17, 2026

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences has initiated a Phase I clinical study of an oral solid dose formulation designed using AI, cleared by the UK's MHRA and conducted at the company's UK facility. The trial—built on machine learning algorithms from partner Intrepid Labs and Quotient's Translational Pharmaceutics platform—aims to validate AI as a direct contributor to formulation design rather than just an upstream analytical tool. Benchling characterizes the broader moment as biotech entering a "builder phase," in which leading organizations embed AI capability at the bench level rather than running isolated pilots.

  • 01Quotient Sciences has dosed healthy volunteers in a Phase I study it describes as the first clinical evaluation of an AI-designed oral formulation, following approval from the UK's MHRA.
  • 02The formulation was developed using advanced machine learning algorithms from Intrepid Labs, integrated with Quotient Sciences' Translational Pharmaceutics platform.
  • 03Benchling identifies a sector-wide shift toward embedding AI capability directly at the bench, moving beyond isolated pilots to structural adoption across biotech R&D.

Jun 17, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

S
Sciences

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512